Antineoplastic Detoxifying Agents Market to Grow at a CAGR of Over 8.1% from 2023 to 2031, reveals Growth Plus Reports
Growth Plus Reports
5 min read
Growth Plus Reports
Newark, New Castle, USA, May 18, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports studied and calculated the size of the global market for antineoplastic detoxifying agents in 2022 and expected it to increase at a revenue CAGR of 8.1% by 2031.
Analysis of the global market for antineoplastic detoxifying agents indicates that during the forecast period, revenue share is likely to increase significantly. Antineoplastic toxicity refers to the negative effects of cancer treatments such as chemotherapy, radiation therapy, immunotherapy, and other targeted therapies.
Key Takeaways:
The rising cases of cancer and the need for chemotherapy are driving the market revenue share.
Advances in antineoplastic detoxifying agents’ formation are developed to increase the safety and effectiveness of chemotherapy treatment.
Liposomal doxorubicin formulations have been shown to reduce the occurrence of cardiotoxicity, a serious side effect of this medicine.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Competitive Landscape
A list of major companies operating in the global market for antineoplastic detoxifying agents includes:
Pfizer Inc.
Global Calcium Pvt. Ltd.
VHB Lifesciences Inc.
Sun Pharmaceuticals Industries Ltd.
Amgen Inc.
Market Drivers and Restraints:
The global antineoplastic detoxifying agents market revenue is driven by the rising number of cancer patients and the requirement for an effective treatment option. Moreover, the growing adoption of chemotherapy as a primary cancer treatment and the development of new and innovative products by pharmaceutical companies.
Market Segmentation:
Based on drug type, the global antineoplastic detoxifying agents market is segmented into palifermin, dexrazoxane, leucovorin, amifostine, levoleucovorin, and others.
Based on cancer type, other antineoplastic detoxifying agents market is segmented into blood cancers, gastro-intestinal cancers, head and neck cancers, breast cancer, and others.
Based on drug type, the dexrazoxane segment dominates the global antineoplastic detoxifying agents market with the largest revenue share. Dexrazoxane is a well-known and commonly used antineoplastic detoxifying drug for decreasing anthracycline-induced cardiotoxicity. Its effectiveness in lowering the occurrence and severity of cardiotoxicity, as well as its acceptable safety profile, have contributed to its domination in the antineoplastic detoxifying agent market share.
Regional Growth Dynamics
Based on the region, North America, with the largest revenue share, dominates the global antineoplastic detoxifying agents market. Due to the high incidence of cancer in the area, there is an increased need for chemotherapeutic medications, which has increased the demand for chemoprotective agents. Furthermore, the dominance of the region in the antineoplastic detoxifying agents market has been boosted by the presence of major market participants in North America as well as the expanding use of newer and more potent chemoprotective agents.
Report Coverage
Growth Plus Reports extensively researched the world market for antineoplastic detoxifying agents. We looked at the basic market traits, important investment spheres, regional growth analytics, ten years of revenue projections, major participants, and mergers and acquisitions.
Table of Content
INTRODUCTION
Market Ecosystem
Timeline Under Consideration
Historical Years – 2021
Base Year – 2022
Forecast Years – 2023 to 2031
Currency Used in the Report
RESEARCH METHODOLOGY
Research Approach
Data Collection Methodology
Data Sources
Secondary Sources
Primary Sources
Market Estimation Approach
Bottom Up
Top Down
Market Forecasting Model
Limitations and Assumptions
PREMIUM INSIGHTS
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2022)
Regulatory Landscape
Reimbursement Scenario
MARKET DYNAMICS
Drivers
Restraints/Challenges
Opportunities
GLOBAL ANTINEOPLASTIC DETOXIFYING AGENTS MARKET - ANALYSIS & FORECAST, BY DRUG TYPE
Palifermin
Dexrazoxane
Leucovorin
Amifostine
Levoleucovorin
Others
GLOBAL ANTINEOPLASTIC DETOXIFYING AGENTS MARKET - ANALYSIS & FORECAST, BY CANCER TYPE
Irrigation Syringe Market by Product Type (Pilot Type Syringe, Grommetless Syringe), Application (Dentistry, ENT Specialist), End User (Hospitals, Clinics) – Global Outlook & Forecast 2023-2031
Healthcare IT Market by Application (Computerized Provider Order Entry Systems, Electronic Prescribing Systems), Component (Software and Hardware), End User (Payers and Providers) – Global Outlook & Forecast 2023-2031
Infertility Drugs Market by Drug Class (Selective Estrogen Receptor Modulators), Procedure Type (Assisted Reproductive Technology, Artificial Insemination), Gender (Male, Female) End User (Hospitals & Clinics, Fertility Centers) - Global Outlook and Forecast 2023-2031
Self Ligating Brackets Market by Product (Active Self Ligating Brackets and Passive Self Ligating Brackets), Material (Metal and Ceramic), End User (Hospitals, Dental Clinics) – Global Outlook & Forecast 2023-2031
Static Compression Therapy Market by Product (Compression Bandages, Compression Garments), End User (Hospitals, Home Care, and Ambulatory Care Centers) – Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020".
